Guggenheim Raises Price Target on ANI Pharma (ANIP) Following 2Q Earnings Report
Tweet Send to a Friend
Guggenheim reiterated a Buy rating on ANI Pharmaceuticals (NASDAQ: ANIP), and raised the price target to $80.00 (from $65.00), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
